| MeSH term | MeSH ID | Detail |
|---|---|---|
| Adenocarcinoma | D000230 | 166 associated lipids |
| Lupus Erythematosus, Systemic | D008180 | 43 associated lipids |
| Lung Neoplasms | D008175 | 171 associated lipids |
| Pancreatic Neoplasms | D010190 | 77 associated lipids |
| Colonic Neoplasms | D003110 | 161 associated lipids |
| Mammary Neoplasms, Experimental | D008325 | 67 associated lipids |
| Body Weight | D001835 | 333 associated lipids |
| Edema | D004487 | 152 associated lipids |
| Precancerous Conditions | D011230 | 48 associated lipids |
| Prostatic Neoplasms | D011471 | 126 associated lipids |
2E,6E-farnesol
2e,6e-farnesol is a lipid of Prenol Lipids (PR) class. 2e,6e-farnesol is associated with abnormalities such as Granulomatous Disease, Chronic, pathologic fistula and Cavitation. The involved functions are known as Regulation, Metabolic Inhibition, cholesterol biosynthetic process, Process and Transcription, Genetic. 2e,6e-farnesol often locates in Plasma membrane, Cytoplasmic matrix, cornified envelope, Epidermis and peroxisome. The associated genes with 2E,6E-farnesol are RAB3A gene, FOSL1 gene, CASP8AP2 gene, RCC1 gene and GALE gene. The related lipids are Sterols, Membrane Lipids and Steroids.
Cross Reference
Introduction
To understand associated biological information of 2E,6E-farnesol, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with 2E,6E-farnesol?
2E,6E-farnesol is suspected in Granulomatous Disease, Chronic, pathologic fistula and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with 2E,6E-farnesol
PubChem Associated disorders and diseases
What pathways are associated with 2E,6E-farnesol
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with 2E,6E-farnesol?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with 2E,6E-farnesol?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with 2E,6E-farnesol?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with 2E,6E-farnesol?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with 2E,6E-farnesol?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with 2E,6E-farnesol
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Llorente-Cortés V et al. | Esterified cholesterol accumulation induced by aggregated LDL uptake in human vascular smooth muscle cells is reduced by HMG-CoA reductase inhibitors. | 1998 | Arterioscler. Thromb. Vasc. Biol. | pmid:9598832 |
| Hampton RY | Genetic analysis of hydroxymethylglutaryl-coenzyme A reductase regulated degradation. | 1998 | Curr. Opin. Lipidol. | pmid:9559264 |
| Aharonson Z et al. | Stringent structural requirements for anti-Ras activity of S-prenyl analogues. | 1998 | Biochim. Biophys. Acta | pmid:9545527 |
| Desrosiers RR and Béliveau R | Regulation by GTPgammaS of protein carboxylmethyltransferase activity in kidney brush border membranes. | 1998 | Arch. Biochem. Biophys. | pmid:9514644 |
| Ura H et al. | Selective cytotoxicity of farnesylamine to pancreatic carcinoma cells and Ki-ras-transformed fibroblasts. | 1998 | Mol. Carcinog. | pmid:9496909 |
| Rajab MS et al. | Antimycobacterial activity of (E)-phytol and derivatives: a preliminary structure-activity study. | 1998 | Planta Med. | pmid:9491760 |
| Roullet JB et al. | Inhibition of Ca2+ uptake into A7r5 vascular smooth muscle cells by farnesol: lack of effect on membrane fluidity and Ca2+-ATPase activities. | 1997 | J. Hypertens. | pmid:9488229 |
| Haklai R et al. | Dislodgment and accelerated degradation of Ras. | 1998 | Biochemistry | pmid:9477957 |
| Hohl RJ et al. | Stereochemistry-dependent inhibition of RAS farnesylation by farnesyl phosphonic acids. | 1998 | Lipids | pmid:9470172 |
| Iazlovitskaia EM et al. | Human leukemia CEM C-1 cells possess a high affinity binding site for farnesol. | 1997 Mar-Apr | Ukr. Biokhim. Zh. | pmid:9463231 |